TICKERNERD
Menu
NKTXNKTXHealthcare · Biotechnology

NKTX Stock Forecast: Nkarta, Inc. Price Predictions for 2026-2027

Last close, 18 Sept 2026
$2.83
+0.71% on the day

The 7 Wall Street analysts covering Nkarta, Inc. hold a median 12-month price target of $11 — +271.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 41 of 100 as at 19 Sept 2026 — in the lower half.

Market cap
$202.7M
Ticker Nerd rank
41 / 100
Median analyst target
$11
Analysts covering
7
Revenue$0.0
Operating income−$43.1M
Net income−$40.4M
Free cash flow−$24.4M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−2.7%
1M
+17.4%
YTD
+53.0%
1Y
+42.2%
From 52W high
−22.9%
From 52W low
+63.6%
$1.73
$3.67
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

NKTX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Nkarta, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 19 Sept 2026
41 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
75
Size
68
Issuance
68
Quality
61
Momentum
60
Value
33
Revisions
27
Growth
22
Volatility
22

Accruals (75): Reported profit is backed by cash, and the company is not expanding recklessly.

Volatility (22): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

NKTX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on NKTX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$5.00$10.00$15.00Oct 25Jan 26Apr 26Jul 26NKTXHigh $14Median $11Low $9

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says7 analysts
7 Buy0 Hold0 Sell
Low $9Median $11High $14

The green dot is the last close — the median target sits +271.0% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
14 Aug 2026StifelMaintainsBuy$11 → $10
11 Aug 2026HC Wainwright & Co.MaintainsBuy$16 → $14
13 May 2026NeedhamReiteratesBuy$11
13 May 2026NeedhamReiteratesBuy—
31 Mar 2026MizuhoMaintainsOutperform—
26 Mar 2026NeedhamMaintainsBuy—
11 Nov 2025StifelMaintainsBuy—
14 Aug 2025StifelMaintainsBuy—
13 Aug 2025NeedhamReiteratesBuy—
10 June 2025MizuhoMaintainsOutperform—
15 May 2025NeedhamMaintainsBuy—
15 May 2025William BlairDowngradeMarket Perform—
9 Apr 2025NeedhamReiteratesBuy—
27 Mar 2025HC Wainwright & Co.ReiteratesBuy—
27 Mar 2025NeedhamReiteratesBuy—
27 Mar 2025StifelMaintainsBuy—
21 Nov 2024MizuhoMaintainsOutperform—
11 Nov 2024HC Wainwright & Co.MaintainsBuy—
8 Nov 2024NeedhamMaintainsBuy—
15 Aug 2024HC Wainwright & Co.MaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. NKTX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

NKTX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 18 Sept 2026, Nkarta, Inc. returned +42.2% against +16.3% for the S&P 500, dividends included.

NKTX vs S&P 500, last 12 monthsTotal return, rebased to 100
80100120140160180200Oct 25Jan 26Apr 26Jul 26NKTXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

NKTX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
2
Fundamentals

Nkarta, Inc. (NKTX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−2.0×

Cheaper than 85% of US stocks

Price / sales
—
Price / book
0.8×

Cheaper than 78% of US stocks

EV / EBITDA
−0.8×

Cheaper than 66% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−38.8%

Higher than 24% of US stocks

Return on assets
−19.6%

Higher than 20% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Nkarta, Inc. (NKTX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Nkarta, Inc. has a market value of $202.7M and an enterprise value of $93.5M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$117.3M.

  • Diluted earnings per share, trailing twelve months: $−1.57.

  • Free cash flow in the twelve months to 30 June 2026: −$93.9M.

  • Shares outstanding: 71.6M.

  • Trailing P/E: −2.0×; forward P/E: −1.6× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Nkarta, Inc. employs 106 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 19 Sept 2026

Data provided by Twelve Data

Peers

NKTX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
NKTXNkarta, Inc.$202.7M
41
CHRSCoherus Oncology, Inc.$201.8M
53
SLGLSol-Gel Technologies Ltd.$196.1M
40
PEPGPepGen Inc.$195.9M
47
ALECAlector, Inc.$208.5M
42
ORMPOramed Pharmaceuticals, Inc.$194.4M
76
TARAProtara Therapeutics, Inc.$209.8M
36

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Nkarta, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest NKTX news & analysis

Nkarta to Participate in September Investor Conferences

GlobeNewsWire · 10 Sept 2026neutral

Nkarta, Inc., a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies for autoimmune diseases, announced it will participate in investor conferences beginning September 16, 2026, including one hosted by H.C. Wainwright. The company is based in South San Francisco, California.

Why it matters — NKTX watchers would care because the company's conference participation offers opportunities for investor visibility and updates on its clinical pipeline.

Nkarta to Present Initial Autoimmune Clinical Data for NKX019 at American College of Rheumatology (ACR) Convergence 2026

GlobeNewsWire · 8 Sept 2026positive

Nkarta announced that it has been selected for three scientific presentations at ACR Convergence 2026, to be held November 6-11 in Orlando, where it will present initial autoimmune clinical data for its engineered NK cell therapy NKX019.

Why it matters — This marks a significant milestone for NKTX watchers as the company prepares to disclose early clinical data for NKX019 in autoimmune diseases at a major rheumatology conference.

FAQ

Frequently asked questions about NKTX stock

What is the NKTX stock price forecast for 2026-2027?

The 7 Wall Street analysts covering Nkarta, Inc. have a median 12-month price target of $11, with estimates ranging from $9 to $14. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is NKTX stock a buy right now?

Of the 7 analysts covering Nkarta, Inc., 7 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Nkarta, Inc. 41 out of 100 across roughly 4,600 US stocks as at 19 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank NKTX?

As at 19 Sept 2026, Nkarta, Inc. ranks 41 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (75 of 100).

Will NKTX stock go up?

No one can know that. What the data says: the median 12-month target from 7 analysts implies +271.0% from the last close, and Ticker Nerd's factor model ranks Nkarta, Inc. 41 out of 100 as at 19 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the NKTX stock forecast for 2030?

No analyst covering Nkarta, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NKTX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $9 to $14 over the next 12 months.

How has NKTX stock performed over the past year?

Nkarta, Inc. returned +42.2% over the 12 months to 18 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Nkarta, Inc. do?

Nkarta, Inc. is a clinical-stage biopharmaceutical company focused on developing allogeneic, off-the-shelf natural killer (NK) cell therapies.

What is the latest news on NKTX?

The most recent item we track (GlobeNewsWire, 10 Sept 2026): "Nkarta to Participate in September Investor Conferences". Nkarta, Inc., a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies for autoimmune diseases, announced it will participate in investor conferences beginning September 16, 2026, including one hosted by H.C. Wainwright. The company is based in South San Francisco, California.

Company

About Nkarta, Inc.

Nkarta, Inc. is a clinical-stage biopharmaceutical company focused on developing allogeneic, off-the-shelf natural killer (NK) cell therapies. The company’s work centers on engineered cell therapies designed to target autoimmune diseases and, in some programs, hematologic cancers. Nkarta’s pipeline includes product candidates built to improve NK-cell recognition, persistence, and activity through proprietary cell engineering and expansion technologies. Its lead programs are being developed for autoimmune conditions such as lupus nephritis, systemic sclerosis, myasthenia gravis, and ANCA-associated vasculitis, reflecting a broader effort to address diseases driven by abnormal immune activity. Based in South San Francisco, California, Nkarta operates as a biotechnology company within the healthcare sector and is dedicated to advancing scalable, ready-to-use cell therapy platforms for clinical use.

CEO Mr. Paul J. Hastings · 106 employees · United States · https://www.nkartatx.com